Uckun F M, Chelstrom L M, Tuel-Ahlgren L, Dibirdik I, Irvin J D, Langlie M C, Myers D E
Wayne Hughes Institute, St. Paul, Minnesota 55113, USA.
Antimicrob Agents Chemother. 1998 Feb;42(2):383-8. doi: 10.1128/AAC.42.2.383.
We have evaluated the clinical potential of TXU (anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate (TXU-PAP) as a new biotherapeutic anti-human immunodeficiency virus (anti-HIV) agent by evaluating its anti-HIV type 1 (anti-HIV-1) activity in vitro, as well as in a surrogate human peripheral blood lymphocyte-severe combined immunodeficient (Hu-PBL-SCID) mouse model of human AIDS. The present report documents in a side-by-side comparison the superior in vitro anti-HIV-1 activity of TXU-PAP compared to the activities of zidovudine, 2',3'-didehydro-2',3'-dideoxythymidine, unconjugated PAP, and B53-PAP, an anti-CD4-PAP immunoconjugate. Notably, TXU-PAP elicited potent anti-HIV activity in the Hu-PBL-SCID mouse model of human AIDS without any side effects and at doses that were very well tolerated by cynomolgus monkeys. Furthermore, plasma samples from TXU-PAP-treated cynomolgus monkeys showed potent anti-HIV-1 activity in vitro.
我们通过评估TXU(抗CD7)-商陆抗病毒蛋白(PAP)免疫缀合物(TXU-PAP)在体外以及在人类艾滋病替代模型——人外周血淋巴细胞-严重联合免疫缺陷(Hu-PBL-SCID)小鼠模型中的抗1型人类免疫缺陷病毒(抗HIV-1)活性,来评估其作为一种新型生物治疗抗人类免疫缺陷病毒(抗HIV)药物的临床潜力。本报告通过并列比较记录了TXU-PAP相较于齐多夫定、2',3'-二脱氢-2',3'-二脱氧胸苷、未缀合的PAP以及一种抗CD4-PAP免疫缀合物B53-PAP在体外具有更优的抗HIV-1活性。值得注意的是,TXU-PAP在人类艾滋病的Hu-PBL-SCID小鼠模型中引发了强大的抗HIV活性,且无任何副作用,其剂量也能被食蟹猴很好地耐受。此外,来自接受TXU-PAP治疗的食蟹猴的血浆样本在体外显示出强大的抗HIV-1活性。